Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane

This study evaluated the effect of surgery-radiotherapy interval (SRI) on outcomes in patients treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) and adjuvant four cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of taxane. From 1999 to 2007, 397 eligibl...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research and treatment 2016, 48(2), , pp.483-490
Main Authors: Koh, Hyeon Kang, Shin, Kyung Hwan, Kim, Kyubo, Lee, Eun Sook, Park, In Hae, Lee, Keun Seok, Ro, Jungsil, Jung, So-Youn, Lee, Seeyoun, Kim, Seok Won, Kang, Han-Sung, Chie, Eui Kyu, Han, Wonshik, Noh, Dong-Young, Lee, Kyung-Hun, Im, Seock-Ah, Ha, Sung Whan
Format: Article
Language:English
Subjects:
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Female
Humans
Lymphatic Metastasis
Mastectomy, Segmental
Original
Radiotherapy, Adjuvant
Taxoids - therapeutic use
Time Factors
의약학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study evaluated the effect of surgery-radiotherapy interval (SRI) on outcomes in patients treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) and adjuvant four cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of taxane. From 1999 to 2007, 397 eligible patients were diagnosed. The effect of SRI on outcomes was analyzed using a Cox proportional hazards model, and a maximal chi-square method was used to identify optimal cut-off value of SRI for each outcome. The median SRI was 6.7 months (range, 5.6 to 10.3 months). A SRI of 7 months was the significant cut-off value for distant metastasis-free survival (DMFS) and disease-free survival (DFS) using a maximal chi-square method. For overall survival, a significant cut-off value was not found. The patients with SRI > 7 months had worse 6-year DMFS and DFS than those with SRI ≤ 7 months on univariate analysis (DMFS, 81% vs. 91%, p=0.003; DFS, 78% vs. 89%, p=0.002). On multivariate analysis, SRI > 7 months did not affect DMFS and DFS. RT delayed for more than 7 months after BCS and adjuvant four cycles of AC followed by four cycles of taxane did not compromise clinical outcomes.
ISSN:1598-2998
2005-9256
DOI:10.4143/crt.2015.111